Switch theme
Sign up to access all valuation multiples
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
2015
68
Last FY Revenue n/a
LTM EBITDA -$114M
-$58.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
RAPT Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$114M.
In the most recent fiscal year, RAPT Therapeutics achieved revenue of n/a and an EBITDA of -$135M.
RAPT Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See RAPT Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$114M | XXX | -$135M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$116M | XXX | -$136M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$109M | XXX | -$130M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, RAPT Therapeutics's stock price is $1.
RAPT Therapeutics has current market cap of $117M, and EV of -$58.3M.
See RAPT Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$58.3M | $117M | XXX | XXX | XXX | XXX | $-2.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, RAPT Therapeutics has market cap of $117M and EV of -$58.3M.
RAPT Therapeutics's trades at n/a EV/Revenue multiple, and 0.4x EV/EBITDA.
Equity research analysts estimate RAPT Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
RAPT Therapeutics has a P/E ratio of -1.1x.
See valuation multiples for RAPT Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $117M | XXX | $117M | XXX | XXX | XXX |
| EV (current) | -$58.3M | XXX | -$58.3M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | 0.5x | XXX | 0.4x | XXX | XXX | XXX |
| EV/EBIT | 0.5x | XXX | 0.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.1x | XXX | -0.9x | XXX | XXX | XXX |
| EV/FCF | 0.7x | XXX | 0.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRAPT Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $2.0M for the same period.
RAPT Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
RAPT Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for RAPT Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -21% | XXX | -18% | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
RAPT Therapeutics acquired XXX companies to date.
Last acquisition by RAPT Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . RAPT Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was RAPT Therapeutics founded? | RAPT Therapeutics was founded in 2015. |
| Where is RAPT Therapeutics headquartered? | RAPT Therapeutics is headquartered in United States of America. |
| How many employees does RAPT Therapeutics have? | As of today, RAPT Therapeutics has 68 employees. |
| Who is the CEO of RAPT Therapeutics? | RAPT Therapeutics's CEO is Dr. Brian Russell Wong, M.D.,PhD. |
| Is RAPT Therapeutics publicy listed? | Yes, RAPT Therapeutics is a public company listed on NAS. |
| What is the stock symbol of RAPT Therapeutics? | RAPT Therapeutics trades under RAPT ticker. |
| When did RAPT Therapeutics go public? | RAPT Therapeutics went public in 2019. |
| Who are competitors of RAPT Therapeutics? | Similar companies to RAPT Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of RAPT Therapeutics? | RAPT Therapeutics's current market cap is $117M |
| Is RAPT Therapeutics profitable? | Yes, RAPT Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of RAPT Therapeutics? | RAPT Therapeutics's last 12 months EBITDA is -$114M. |
| What is the current EV/EBITDA multiple of RAPT Therapeutics? | Current EBITDA multiple of RAPT Therapeutics is 0.5x. |
| What is the current FCF of RAPT Therapeutics? | RAPT Therapeutics's last 12 months FCF is -$81.4M. |
| What is the current EV/FCF multiple of RAPT Therapeutics? | Current FCF multiple of RAPT Therapeutics is 0.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
